Connection

Rolando Cimaz to Antibodies, Monoclonal

Back to Details
This is a "connection" page, showing publications Rolando Cimaz has written about Antibodies, Monoclonal.
Rolando Cimaz
Connection Strength
0.307
Antibodies, Monoclonal
  1. Canakinumab for the treatment of TNF-receptor associated periodic syndrome. Expert Rev Clin Immunol. 2017 06; 13(6):513-523.
    View in: PubMed
    Score: 0.174
  2. Unveiling the Efficacy, Safety, and Tolerability of Anti-Interleukin-1 Treatment in Monogenic and Multifactorial Autoinflammatory Diseases. Int J Mol Sci. 2019 Apr 17; 20(8).
    View in: PubMed
    Score: 0.049
  3. Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018 Aug; 37(8):2233-2240.
    View in: PubMed
    Score: 0.046
  4. Complications of systemic juvenile idiopathic arthritis: risk factors and management recommendations. Expert Rev Clin Immunol. 2015 May; 11(5):575-88.
    View in: PubMed
    Score: 0.037
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.